LAG3 and cancer: Our data show that GB265, GB266, and GB266T have superior performance to these antibody combinations in assays that mimic the general characteristics of the TME, and could represent a better approach to target the PD-1, TIGIT and LAG-3 immune checkpoints in immunotherapy of cancers.